[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495682":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":39,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":54,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Insel Gruppe AG, University Hospital Bern","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"David J Seiffge, Prof, MD","Department of Neurology, Inselspital Bern University Hospital","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Marianne Kormann","CONTACT","+41 31 632 70 00","studien.stroke@insel.ch",[20],{"facility":11,"status":21,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Bern","3010","Switzerland","CH",{"type":27,"coordinates":28},"Point",[29,30],7.44744,46.94809,{"lat":30,"lon":29},[33,36],{"name":34,"role":16,"phone":17,"phoneExt":7,"email":35},"David J Seiffge, MD, Prof","david.seiffge@insel.ch",{"name":37,"role":38,"phone":7,"phoneExt":7,"email":7},"Martina B Goeldlin, MD","SUB_INVESTIGATOR",{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100495682","prognosis-of-cerebral-small-vessel-disease-100495682",false,"NCT05734378","Prognosis of Cerebral Small Vessel Disease","Prognosis of Cerebral Small Vessel Disease - a Prospective Cohort Study (PRO-SVD)","PRO-SVD","Inclusion Criteria:\n\n* Hypertensive deep perforator arteriolopathy (DPA), clinically symptomatic with either ICH, ischaemic stroke, cognitive impairment or severe radiological manifestation (Fazekas ≥II)\n* Cerebral amyloid angiopathy (CAA according to modified Boston or Edinburgh criteria), clinically symptomatic with either ICH (including cSAH), amyloid spells, cognitive impairment or severe radiological manifestation (CMB≥2)\n* Other SVD (i.e. CADASIL or other sporadic or genetic SVD)\n\nExclusion Criteria:\n\n* Life expectancy of \\\u003C6 months due to not-SVD related causes (i.e. cancer)\n* Patient is unlikely to attend follow-up visits","ALL","16 Years",{"count":52,"type":53},900,"ESTIMATED","1 Year","OBSERVATIONAL","Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation.\n\nThe aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients with SVD according to the type of index presentation.",[58,59,60,61],"Cerebral Amyloid Angiopathy","Small Vessel Cerebrovascular Disease","Cadasil","CAA - Cerebral Amyloid Angiopathy",[63,64,65,66,67,68],"small vessel disease","CAA","cerebral amyloid angiopathy","hypertensive arteriopathy","deep perforator arteriopathy","CADASIL","2023-03-06",{"date":71,"type":72},"2023-03-08","ACTUAL",{"date":74,"type":72},"2020-12-01",{"date":76,"type":53},"2030-11-30",{"name":5,"class":6},1]